Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic and Predictive Value of Tumor Molecular Alterations in Patients With Prostate Cancer

NCT04983628 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT04983628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic and Predictive Value of Tumor Molecular Alterations in Patients With Prostate Cancer
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2020
Completion date
August 1, 2023
Enrollment
250 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

germline brca1 gene mutation, germline brca2 gene mutation, mutation, prostate cancer metastatic, prostate cancer recurrent